Strengthening HPV Vaccination and Adolescent Health Research Program in Nigeria (SHARP)
NCT07200414 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12654
Last updated 2026-04-13
Summary
The goal of this clinical trial is to learn whether adding adolescent health services to routine government health programs can increase Human Papillomavirus (HPV) vaccination coverage among 9-year-old girls and improve use of other health services by adolescents in Nigeria. The main questions it aims to answer are:
Does offering an integrated package of adolescent health services increase the proportion of 9-year-old girls who receive the HPV vaccine?
Does this package increase use of other services such as reproductive health counseling, nutrition and vision screening, mental health services, and deworming among girls and boys ages 9-15 years?
Researchers will compare areas that receive the integrated package to areas that continue with the standard government services to see if the intervention improves vaccination and health service use.
Participants will:
Be surveyed about HPV vaccination and health service use before and after the program is offered.
Take part in interviews or focus groups about experiences with adolescent health services.
Be offered HPV vaccination and other adolescent health services through local health facilities.
Conditions
- Human Papillomavirus (HPV) Vaccine
- Human Papillomavirus (HPV) Vaccines
- Human Papillomavirus (HPV) Infections
- Adolescent Health Services
Interventions
- BEHAVIORAL
-
Integrated Adolescent Health Package
Delivery of an integrated package of adolescent health services through government health facilities. The package includes HPV vaccination, sexual and reproductive health counseling, general health check-ups, nutrition and vision screening, mental health support, deworming, and dental and oral health services. Implemented in intervention LGAs in Lagos and Kebbi States.
- OTHER
-
Routine Government Health Services
Routine government health services provided in comparison LGAs. Services may include HPV vaccination as per national immunization schedules and other adolescent health services delivered under existing programs, but without the integrated package.
Sponsors & Collaborators
-
Direct Consulting and Logistics
collaborator UNKNOWN -
Jhpiego
collaborator OTHER -
Gavi, The Vaccine Alliance
collaborator OTHER -
Johns Hopkins Bloomberg School of Public Health
lead OTHER
Principal Investigators
-
Chizoba Wonodi, MBBS, DrPH, MPH · Johns Hopkins University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 9 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-10-01
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
Countries
- Nigeria
Study Locations
More Related Trials
-
Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)
NCT00092495 ·Status: COMPLETED ·Phase: PHASE3
-
Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
NCT00520598 ·Status: COMPLETED ·Phase: PHASE2
-
The Prospective Cohort Study to Evaluate the Preventive Efficacy of HPV Vaccine in Japanese Women Aged 27-45 Years
NCT04022148 ·Status: UNKNOWN
-
GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
NCT01245764 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females
NCT01462357 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
NCT03158220 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)
NCT00365378 ·Status: COMPLETED ·Phase: PHASE2
-
A Cohort Study to Assess Sustained Immunogenicity to qHPV Vaccine Among HIV-infected Girls and Boys Age 9-14 Years
NCT01446718 ·Status: COMPLETED
-
Vaccine Effectiveness of One Dose of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Young-adult Women in Sweden Among Women Participating in a Clinical Trial of Concomitant HPV Vaccination and Screening
NCT07314307 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV
NCT03284866 ·Status: COMPLETED ·Phase: PHASE3
-
Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting
NCT00572832 ·Status: COMPLETED ·Phase: NA
-
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
NCT05266898 ·Status: RECRUITING ·Phase: PHASE4
-
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18
NCT00122681 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
NCT01047345 ·Status: COMPLETED ·Phase: PHASE3
-
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
NCT05580341 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
NCT00943722 ·Status: COMPLETED ·Phase: PHASE3
-
Gardasil Administration
NCT03123419 ·Status: WITHDRAWN ·Phase: NA
-
Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)
NCT02653118 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)
NCT00090220 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years
NCT00306241 ·Status: COMPLETED ·Phase: PHASE3
-
GARDASIL Reexamination Study (V501-059)
NCT01062074 ·Status: COMPLETED
-
Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls
NCT01381575 ·Status: COMPLETED ·Phase: PHASE3
-
Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden
NCT04910802 ·Status: RECRUITING ·Phase: PHASE4
-
A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia
NCT07256912 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)
NCT00733122 ·Status: WITHDRAWN ·Phase: PHASE3